Werewolf Therapeutics, INC Form 4 insider transactions

Director Luke Evnin reported transactions involving the sale of Werewolf Therapeutics, Inc. (HOWL) common stock, executed under a Rule 10b5-1 trading plan.

Luke Evnin, a Director at Werewolf Therapeutics, Inc., reported transactions involving the sale of common stock under a Rule 10b5-1 trading plan.

RA Capital Management has disclosed the sale of approximately 448,850 shares of Werewolf Therapeutics (HOWL) across three trading days in June 2026.

RA Capital Management has disclosed the sale of 678,226 shares of Werewolf Therapeutics (HOWL) across three days in June 2026.

Director Luke Evnin of Werewolf Therapeutics, Inc. reported the sale of 76,928 shares of common stock via a Rule 10b5-1 trading plan.

Director Luke Evnin of Werewolf Therapeutics, Inc. reported the sale of 105,565 shares of common stock via a Rule 10b5-1 trading plan.

Director Luke Evnin of Werewolf Therapeutics, Inc. reported the sale of 139,803 shares of common stock via a Rule 10b5-1 trading plan.

Werewolf Therapeutics director Luke Evnin sold 141,106 shares of common stock across three days in late May 2026.

Luke Evnin, a Director at Werewolf Therapeutics, reported the sale of common stock totaling 192,362 shares across multiple transactions between May 21 and May 26, 2026, pursuant to a Rule 10b5-1 trading plan.

Director Luke Evnin of Werewolf Therapeutics, Inc. reported the sale of 171,049 shares of common stock via a Rule 10b5-1 trading plan.

Director Luke Evnin reported a sale of 44,679 shares of Werewolf Therapeutics common stock for approximately $0.54 per share, executed under a Rule 10b5-1 trading plan.

Director Luke Evnin reported the sale of 407,574 shares of Werewolf Therapeutics, Inc. common stock via a Rule 10b5-1 plan.

RA Capital Management has disclosed the sale of 564,449 shares of Werewolf Therapeutics (HOWL) across three trading days in May 2026.

Director Luke Evnin of Werewolf Therapeutics, Inc. reported the sale of 100,581 shares of common stock via a Rule 10b5-1 trading plan.

Director Luke Evnin of Werewolf Therapeutics, Inc. reported the sale of 274,619 shares of common stock via a Rule 10b5-1 trading plan.

Director Luke Evnin of Werewolf Therapeutics, Inc. sold 205,911 shares of common stock over three days in late April 2026.

Werewolf Therapeutics Director Luke Evnin sold 38,782 shares of common stock at a weighted average price of $0.54 per share, executed under a pre-arranged 10b5-1 plan.

Werewolf Therapeutics Director Luke Evnin reported the sale of over 111,000 common shares through pre-arranged 10b5-1 plans.

A director at Werewolf Therapeutics, Luke Evnin, sold a significant number of common shares across three transactions in early January 2026, pursuant to a pre-established 10b5-1 plan.

Luke Evnin, a Director at Werewolf Therapeutics, Inc., reported the sale of common stock totaling 71,054 shares over three days in January 2026, executed under a pre-established 10b5-1 trading plan.

Luke Evnin, a Director and 10% owner of Werewolf Therapeutics, Inc., reported sales of common stock totaling 78,377 shares across three transactions in late 2025 and early 2026 under a Rule 10b5-1 plan.

A director at Werewolf Therapeutics, Luke Evnin, reported the sale of 291,283 common shares through various entities under a pre-established 10b5-1 plan.

A director and 10% owner of Werewolf Therapeutics, Luke Evnin, reported the sale of 48,171 shares of common stock over three days in December 2025.

Werewolf Therapeutics Director Luke Evnin reported sales of common stock totaling 82,971 shares across three days in December 2025, executed under a Rule 10b5-1 plan.

Luke Evnin, a Director and 10% owner of Werewolf Therapeutics, Inc., reported multiple sales of common stock totaling 95,179 shares in early December 2025.

Luke Evnin, a Director at Werewolf Therapeutics, Inc., reported the sale of 128,185 shares of common stock over three days in early December 2025, pursuant to a pre-established 10b5-1 plan.

MPM BioVentures 2014, a former 10% owner of Werewolf Therapeutics, Inc., reported the sale of nearly 200,000 common shares over three days in December 2025.

Ansbert Gadicke and affiliated entities, former 10% owners of Werewolf Therapeutics, Inc., sold nearly 200,000 shares of common stock over three days in December 2025.

A director of Werewolf Therapeutics, Luke Evnin, reported multiple indirect sales of common stock totaling 91,088 shares in late November and early December 2025.

MPM BioVentures 2014, a 10% owner and director, reported multiple sales of Werewolf Therapeutics common stock totaling 141,927 shares in late November and early December 2025 under a Rule 10b5-1 plan.